Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05653999 · ClinicalTrials.gov registry record
Assessing Speech Perception and Amplification Benefit During Infancy
A clinical trial, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- 36
- Enrollment target
NCT05653999: Completed study, sponsored by University of Colorado, Denver.
NCT05653999 is a clinical trial that has completed, run by University of Colorado, Denver. The registered enrollment target is 36 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05653999 has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- 36 participants
- Enrollment target
Study Summary
The goal of this project is to compare aided and unaided speech discrimination among infants with hearing loss and a cohort of infants with typical hearing. Working Hypothesis: Among this group of infants with hearing loss, performance will be significantly better when infants are tested while using amplification (i.e., aided condition) compared to when tested without amplification (i.e., unaided condition). Infants fit with optimally programmed amplification will perform similarly to the infants with typical hearing on speech discrimination tasks.
Primary Outcome
To measure speech perception ability, infants are trained to complete a task in response to a change in a speech sound played over a speaker. Scores are given in d' (or equivalent) and are calculated from both true and false responses. Scores can range from 0.97 and 3.00. Scores above 1.2 are considered significantly above chance indicating successful perception of speech contrasts. To separate issues such as speech discrimination abilities versus proper conditioning, if a child is unable to dis
Interventions
- DEVICE Hearing Aids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2023-03-10 |
| Est. Completion | 2025-05-28 |
What the finished NCT05653999 record still lists
NCT05653999 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 36 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Hearing Aids is the first listed.
NCT05653999 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05653999 about?
NCT05653999 is a clinical study titled "Assessing Speech Perception and Amplification Benefit During Infancy". The goal of this project is to compare aided and unaided speech discrimination among infants with hearing loss and a cohort of infants with typical hearing. Working Hypothesis: Among this group of infants with hearing loss, performance will be significantly better when infants are tested while usin...
What is the current status of trial NCT05653999?
This trial is currently completed. The enrollment target is 36 participants. The study started on 2023-03-10. Estimated completion is 2025-05-28.
What interventions are being tested in trial NCT05653999?
The interventions under investigation include: Hearing Aids (DEVICE).
Who is sponsoring clinical trial NCT05653999?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI